TOKYO, Mar 17 (Pulse News Wire) – Modalis Therapeutics Corporation (4883.T) reported the exercise of its 17th series warrants (with adjustment clause) issued to EVO Fund during the period from March 2 to March 17, 2026. A total of 21,500 warrants were exercised out of 192,000 outstanding warrants, representing a ratio of 11.2%.
As of February 28, 2026, there were 65,800 unexercised warrants remaining, which now stands at 44,300 warrants. During the reporting period, the company delivered shares corresponding to warrant exercises totaling 2,150,000 shares.
On March 5, 2,800 warrants were exercised at an exercise price of ¥54 per share, resulting in the issuance of 15,600 shares. Additionally, on March 6, another 2,800 warrants were exercised at ¥56 per share, leading to the issuance of 280,000 shares.
On March 17, 250,000 warrants were exercised at ¥57 per share, resulting in the issuance of 2,500 shares.
🟢 Confidence: High AI-translated content.